• AC Immune SA ACIU.OQ reported quarterly adjusted earnings of 5 rappen​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -18 rappen. The mean expectation of four analysts for the quarter was for a loss of 20 rappen per share. Wall Street expected results to range from -20 rappen to -19 rappen per share.

• Revenue was CHF25.49 million​; analysts expected $1.48 million.

• AC Immune SA's reported EPS for the quarter was 5 rappen​.

• The company reported quarterly net income of $5.5 million.

• AC Immune SA shares had fallen by 14.3% this quarter and lost 35.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for AC Immune SA is $8.50

This summary was machine generated from LSEG data November 6 at 05:19 a.m. UTC. ​All figures in Swiss francs unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)